2020
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma
Hegde M, Joseph SK, Pashankar F, DeRenzo C, Sanber K, Navai S, Byrd TT, Hicks J, Xu ML, Gerken C, Kalra M, Robertson C, Zhang H, Shree A, Mehta B, Dakhova O, Salsman VS, Grilley B, Gee A, Dotti G, Heslop HE, Brenner MK, Wels WS, Gottschalk S, Ahmed N. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nature Communications 2020, 11: 3549. PMID: 32669548, PMCID: PMC7363864, DOI: 10.1038/s41467-020-17175-8.Peer-Reviewed Original ResearchConceptsHER2-CAR T cellsCAR T cellsT-cell infusionCAR T-cell infusionT cellsMetastatic rhabdomyosarcomaOngoing phase I trialPhase I trialT cell receptorSecond remissionI trialSerum autoantibodiesImmune reactivityDetectable diseaseTumor responseBone marrowResponse consolidationInfusionRhabdomyosarcomaImmunodominant clonesLymphodepletionRemissionPathway proteinsDiseaseMonths
2019
Sustained Remission After Maintenance Irinotecan in Patient With Multiply Relapsed Hepatoblastoma
Natarajan E, Auerbach C, Cheron R, Pashankar F. Sustained Remission After Maintenance Irinotecan in Patient With Multiply Relapsed Hepatoblastoma. Journal Of Pediatric Hematology/Oncology 2019, 42: e659-e661. PMID: 31259823, DOI: 10.1097/mph.0000000000001544.Peer-Reviewed Original ResearchConceptsRecurrent hepatoblastomaIfosfamide/carboplatin/etoposide chemotherapyLong-term disease-free survivalCarboplatin/etoposide chemotherapyDisease-free survivalLimited treatment optionsAdjuvant chemotherapySecond relapseEtoposide chemotherapyFirst relapseMultiple relapsesSurgical resectionPoor prognosisTreatment optionsMetastatic hepatoblastomaHepatoblastomaRelapseChemotherapyIrinotecanChildrenRemissionResectionPostresectionPatientsPrognosis
2014
Rituximab for the Treatment of Acute Refractory ITP
Kim SG, Whyte D, Pashankar FD. Rituximab for the Treatment of Acute Refractory ITP. Journal Of Pediatric Hematology/Oncology 2014, 36: e149-e151. PMID: 23669737, DOI: 10.1097/mph.0b013e318292f006.Peer-Reviewed Original ResearchConceptsRefractory immune thrombocytopenic purpuraImmune thrombocytopenic purpuraFirst-line therapyTreatment of ITPAcute immune thrombocytopenic purpuraSecond-line therapySustained remissionIntravenous immunoglobulinIntravenous rituximabEffective regimenImmune globulinAcute settingThrombocytopenic purpuraCombined therapyRituximabMost childrenTherapyClear consensusTreatmentCorticosteroidsRemissionPurpuraRegimenPatientsImmunoglobulin